Skip to content
sellModerate cluster of 2

Christine A Poon sold $4.3M of REGN

director at REGENERON PHARMACEUTICALS, INC.. 6,500 shares at an average of $654.27, traded Oct 29, 2025, filed Oct 31, 2025.

Warning score
53
Value
$4.3M
6,500 shares
Holdings after
2,352
-73% from before
From 52-week low
+35%
low $479.88, close $649.58
From 52-week high
-29%
high $918.66, as of Oct 29, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $4.3M at market
    +25
  • Share of holdings sold
    Sold 73% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

REGNOct 9, 2026 · close 746.54
Since filing Oct 31, 2025: +15.1%SPY +15.4% · excess -0.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001189014-25-000005, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 29, 2025MOption exercise
Common Stock
+6,500$520.01$3.4M8,852Oct 31, 2025
Oct 29, 2025SOpen-market sale
Common Stock
-650$652.68$424k8,202Oct 31, 2025
Oct 29, 2025SOpen-market sale
Common Stock
-2,735$653.50$1.8M5,467Oct 31, 2025
Oct 29, 2025SOpen-market sale
Common Stock
-1,915$654.42$1.3M3,552Oct 31, 2025
Oct 29, 2025SOpen-market sale
Common Stock
-100$655.10$66k3,452Oct 31, 2025
Oct 29, 2025SOpen-market sale
Common Stock
-712$656.50$467k2,740Oct 31, 2025
Oct 29, 2025SOpen-market sale
Common Stock
-388$657.29$255k2,352Oct 31, 2025
Oct 30, 2025MOption exercise
Common Stock
+2,712$520.01$1.4M5,064Oct 31, 2025
Oct 29, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative
-6,500$0.00$02,712Oct 31, 2025
Oct 30, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative
-2,712$0.00$00Oct 31, 2025

Related signals

Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
13Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Kathryn Guarini
director
$340k
400 shares
-40%
33Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Marion McCourt
EVP Commercial
$2.0M
2,346 shares
-16%
15Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Bonnie L Bassler
director
$1.2M
1,500 shares
-47%
17Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Bonnie L Bassler
director
$570k
760 shares
-33%
44Moderate
REGNsell 3
REGENERON PHARMACEUTICALS, INC.
Jason Pitofsky
VP Controller
$281k
431 shares
-9%
3Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Marion McCourt
EVP Commercial
$845k
1,000 shares
-7%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Christine A Poon sold $4.3M of REGN | InsiderTell